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Background: Increasing evidence implicates involvement of the innate immune
system in the initiation and progression of Parkinson’s disease (PD). Monocytes
and monocyte-derived cells perform a number of functions, such as phagocytosis,
chemotaxis, and cytokine secretion, which may be particularly relevant to PD pathology.
The behavior of these cells in early-moderate disease, in conditions more similar to the
in-vivo environment has not been fully evaluated.
ResearchQuestion: Doesmonocyte function, including phagocytosis, chemotaxis and
cytokine secretion, differ in early-moderate PD compared to age and gender-matched
controls?
Methods: Participants included PD patients (n= 41) with early-moderate stage disease
(Hoehn and Yahr ≤2) and age and gender matched controls (n = 41). Peripheral blood
mononuclear cells (PBMCs) were isolated from whole blood and monocytes were further
separated using CD14 magnetic beads. Functional assays, including bead phagocytosis
(in standard medium and autologous serum), Boyden chamber trans-well chemotaxis,
and cytokine secretion on lipopolysaccharide stimulation were performed. Monocyte
surface markers relating to chemotaxis were measured using immunohistochemistry and
flow cytometry. Between-group analysis was performed using paired t-tests.
Results: An autologous serum environment significantly increased bead phagocytosis
compared to standard medium as expected, in both patients and controls. When in
autologous serum, PD monocytes demonstrated enhanced phagocytosis compared to
control monocytes (p = 0.029). The level of serum-based phagocytosis was influenced
by complement inactivation and the origin of the serum. There were no significant
differences between PD and controls in terms of standard medium based monocyte
migration or cytokine secretion in this cohort.
Conclusions: Autologous serum has a significant influence on monocyte phagocytosis
and reveals increased phagocytic capacity in early-moderate PD compared to controls.
These conditions may better reflect the function of monocytes in-vivo in PD patients
than standard medium based phagocytosis assays. Further studies will be required to
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replicate these results in larger cohorts, including earlier and later stages of disease, and
to understand which serum factors are responsible for this observation and the potential
mechanistic relevance to PD pathogenesis.
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INTRODUCTION
There is increasing evidence of an association between the
innate immune system and Parkinson’s disease (PD), with
genetic, cellular and biomarker studies suggesting variations in
innate immune genes and cells in this condition (1). A few
studies have found peripheral innate immune changes in PD
patients, including changes in peripheral monocyte phenotype
and function (2–4), but results are inconsistent between studies
andmay be related to variations in participant characteristics and
assay protocols.
Monocytes are a major component of the peripheral innate
immune system and have a number of important functions,
such as migration into tissues, phagocytosis of pathogens
and cell debris, secretion of cytokines and other proteins,
antigen presentation to cells of the adaptive immune system
and differentiation into dendritic cells and macrophages which
take on more specialized roles (5). The 3 principal subtypes
of monocyte–classical, intermediate and non-classical-specialize
in different combinations of functions. However, there is a
considerable degree of overlap, and variability between study
findings suggests that the functional abilities of monocytes may
vary depending on a variety of intrinsic and extrinsic factors
(5–8).
With relevance to PD pathology, monocytes and related
cells, such as macrophages have been found to be capable of
entering and interacting with the central nervous system via the
meninges and choroid plexus (9, 10) and may be involved in
the recognition and/or phagocytosis of protein aggregates (11–
13), of debris from degenerating neurons and other cells, or of
microbial organisms and their components. However, this may
not be entirely beneficial, as they may also generate inflammatory
cytokines, such as IL-1β in response to TLR and inflammasome
stimulation by forms of alpha-synuclein or other pathogen or
damage associated molecular patterns (PAMPs and DAMPs)
(12), which in turn may then drive an ongoing inflammatory
response. Monocyte derived cells may also conceivably play a
role in the presentation of pathogenic alpha-synuclein and other
antigens, to T lymphocytes, mediated by the PD-associated risk
allele HLA-DR (14–16). These functions may occur within the
intravascular compartment, ormonocytes could alsomigrate into
tissues to function as monocytes or differentiated cells, such as
dendritic cells and macrophages (15).
Studies on peripheral monocyte function in PD to date have
reported impaired phagocytosis, with higher monocyte alpha-
synuclein levels associated with greater phagocytic impairment
(2, 3). Uptake of alpha-synuclein fibrils by monocytes (12)
has been shown to increase production of pro-inflammatory
cytokines, such as IL-1β, while monocyte uptake of alpha-
synuclein oligomers has been reported to decrease with age (11).
Monocyte cytokine secretion in response to stimulation has been
found to be increased (3, 17) or decreased (4) in PD compared to
controls in separate studies. No studies have assessed monocyte
migration in PD, but alpha-synuclein monomers and oligomers
have been found to act as monocyte chemotactic factors (18).
While studies to date have not been entirely consistent, they
have provided some indication that there may be differences in
monocyte function between PD and controls. However, most
studies have been performed on relatively late stage PD patients
with average disease duration of at least 8–10 years, in whom
secondary effects of the disease process on the innate immune
system are likely to be predominant. Functional differences in
monocytes of PD patients at an earlier disease duration and stage
than in these previous studies, have not been fully assessed.
Functions, such as phagocytosis may also be affected by
changes in cell surface marker expression and properties, which
occur on prolonged incubation in different forms of artificial
media (19). Thus, assessment of functional phagocytic differences
in conditions which more closely replicate the in-vivo state, with
less pre-incubation and an autologous serum environment, may
also be important in order to obtain a better understanding of
monocyte function in PD.
Therefore, this study investigated key functions of ex-vivo
monocytes (phagocytosis, migration and cytokine secretion), in
early-moderate PD patients [Hoehn and Yahr (HY) stage ≤2,
mean disease duration 4.2 ± 1.1 years] and age and gender
matched controls, using conditions more representative of the in-
vivo state where possible. Monocyte migration-related markers
[CCR2, C-X3-C motif chemokine receptor 1 (CX3CR1)] were
also evaluated using immunocytochemistry and flow cytometry.
MATERIALS AND METHODS
Participant Recruitment and Sample
Collection
The study was carried out and the protocol was approved in
accordance with the recommendations of the Cambridgeshire
Research Ethics Committee (03/303), with written, informed
consent from all subjects in accordance with the Declaration of
Helsinki. Patients were recruited from the PD Research Clinic at
the John van Geest Centre for Brain Repair in Cambridge.
Inclusion criteria were fulfillment of UK PD Brain Bank
Criteria for a diagnosis of PD, age 55–80 years and Hoehn
and Yahr (HY) stage ≤2 as defined by the Movement Disorder
Society, with absence of postural instability (20). Exclusion
criteria were: other neurodegenerative disorders, chronic
inflammatory or autoimmune disorders, current clinically
significant infection, surgery within last month, vaccinations in
the last 3 weeks, use of anti-inflammatory/immunomodulatory
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medications [steroids (within 3 months), high dose aspirin
>75mg (2 weeks), ibuprofen and other nonsteroidal
anti-inflammatory drugs (2 weeks) and other long-term
immunosuppressant drugs e.g., azathioprine, mycophenolate,
methotrexate, rituximab or other antibody therapy (1 year)].
Control participants were recruited from the NIHR
Cambridge BioResource (http://www.cambridgebioresource.
org.uk). They were age and gender matched to the patients and
had no history of neurological disease, self-reported memory
problems or depression. Exclusion criteria for controls were the
same as for the patients.
50ml venous blood was collected (45ml lithium heparin and
5ml serum in Sarstedt, S-Monovette R© tubes) between 9 and
11 a.m. and patients were on their regular medication and had
no dietary restrictions. Serum was extracted by centrifuging
samples at 2,000 rpm for 15min, following 15min clotting
time. Separated serum was stored at 4◦C prior to subsequent
processing. PBMCs were isolated for immunohistochemistry and
flow cytometry. Functional assays were performed on fresh cells
and serum, depending on cell availability. Patient and paired
control samples were processed together on the same day.
Basic demographic and clinical data were obtained from
the patients and included disease duration, medication history,
Unified Parkinson’s Disease Rating Scale (UPDRS) score and
Addenbrooke’s Cognitive Examination-Revised (ACE-R) score.
Separate data from this participant cohort contributed toward
our previously published study investigating T cell senescence in
PD (21).
PBMC Isolation, Immunocytochemistry
and Flow Cytometry
PBMCs were extracted using the standard Ficoll gradient
centrifugation method (Ficoll R© Paque Plus, GE Healthcare).
Cell suspensions were centrifuged, and cell pellets were blocked
with fluorescence activated cell sorting (FACS) buffer with 2%
mouse serum (Sigma) per 0.5–1 × 106 cells. Following blocking
for 30min, the PBMCs were stained with a panel of relevant
conjugated antibodies including [CX3CR1-APC and CCR2-PE
(Biolegend)] or appropriate isotype controls [Rat IgG2b κ-APC
and Mouse IgG2a κ-PE (Biolegend)] and incubated at 4◦C for
30min. Following incubation, the PBMCs were washed and then
fixed with 2% paraformaldehyde (PFA) and re-suspended in
FACS buffer for flow cytometry. Flow cytometry was performed
using the BD LSR Fortessa machine with BD FACSDiva software.
Monocytes were gated as described in the literature (22)
(Supplementary Figure 4) and a minimum number of 10,000
monocyte events were collected per sample. PBMCs from healthy
controls, labeled with single conjugated antibodies, were used to
determine the appropriate compensation for spectral overlap of
fluorophores.
Flow cytometry data was analyzed using Flow Jo software,
version 10. The percentage of positive cells and marker
expression levels were determined with reference to isotype
control samples (Median Fluorescence Intensity (MFI)
Test/Isotype ratio).
Monocyte Separation
CD14+ cells were separated using MACS R© magnetic CD14+
beads (Miltenyi Biotec) and “LS” columns, according to the
manufacturer’s instructions. Patient and control pairs were
separated using the same method. CD14+ cell purity following
magnetic bead separation was>97% (CD14-APC-H7, Biolegend;
Supplementary Figure 1A). The monocytes obtained following
CD14+ magnetic bead separation undertaken in standard cooled
conditions produced consistent patterns of CD14/CD16 staining,
demonstrating the presence of all monocyte subtypes (Classical,
Intermediate and Non-Classical; Supplementary Figure 1B).
Monocyte Bead Phagocytosis Assays
CD14+ cells were centrifuged at 350 g for 5min and re-
suspended in either phenol-red free, clear RPMI (Life
Technologies) + 10% heat inactivated FCS (Sigma), or in
100% of the participant’s own serum (200 µl per 0.5 × 106
monocytes). The cells were placed in 96 well-plates at a density
of 0.5× 106 monocytes in 200 ul per well and equilibrated in the
incubator (37◦C, 5% CO2; Test plates) or the fridge (4
◦C plates)
for 45min.
Latex beads [Fluorescent Carboxyl Polymer, Dragon green,
2–5µm (Bangs Laboratories)] were added at a 1:1 ratio and
mixed into the appropriate wells. The Test plates were placed
in the incubator (37◦C, 5% CO2) to simulate in-vivo conditions.
Reference plates were placed in the fridge (4◦C) to inhibit
monocyte phagocytosis and endocytosis and used as a reference
to account for non-specific adherence of fluorescent beads to
the cells for each condition. Cells were incubated for 60min,
then washed with ice cold PBS and then with FACS buffer.
Cells were fixed in 2% PFA prior to flow cytometry (BD LSR
Fortessa). The gating strategy is illustrated in Figure 1. The bead
positive monocyte percentage and bead positive monocyte MFI
ratio values for bead uptake were calculated with reference to
the 4◦C samples (Bead positive monocyte % = Test sample bead
positive monocyte %−4C sample bead positive monocyte %;
Bead positive monocyte MFI ratio = Test sample bead positive
MFI/4C sample bead positive MFI).
The effect of heat mediated serum complement inactivation
on these serum bead uptake assays was assessed by heating the
serum to 56◦C for 30min prior to performing the assay.
Microscopy was performed on a subset of samples. The cells
were re-suspended in PBS and smeared onto a glass slide and
air dried with protection from light. A glass cover slip was
applied onto the slide with FluorSaveTM reagent solution. Light
microscope images of latex bead uptake were taken on the Leica
DM light microscope.
Monocyte Migration Assays
Monocyte migration assays were performed using Neuro
Probe ChemoTx R© chemotaxis system 96 well-plates with 5µm
pores (http://www.neuroprobe.com/product/chemo_tx/). 29 µl
of medium (RPMI (Life Technologies) and 10% FCS) with or
without the chemoattractant CCL2 (100 ng/ml; Peprotech) was
added to the appropriate lower wells of the plate in triplicate.
50 µl of monocyte suspension (2 × 105 monocytes per 50 µl
RPMI and 10% FCS) was added to the top of the filter above
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FIGURE 1 | (A) Light microscope image of monocytes with phagocytosed 2–5µm latex beads (×20). (B) Flow cytometry gating strategy for monocyte latex bead
phagocytosis (1:1 ratio) analysis. Monocyte gate extended upwards to include bead phagocytosed monocytes, which have increased side scatter. Dividing gate on
histogram based on position of 4◦C sample. FSC-A, forward scatter-area; FSC-W, forward scatter-width; SSC-A, side scatter-area. (C,D) Monocyte latex bead
phagocytosis in standard medium and in autologous serum–(C) percentage bead positive monocytes (37–4◦C); (D) bead positive monocyte median fluorescence
intensity (MFI) ratio (37/4◦C) [Medium-PD = 34, Controls = 39; Serum-PD = 25, Controls = 27; p-values relate to the significance of paired t-tests performed
between matched PD and control pairs following the exclusion of experimental outliers >3 SD above or below mean (excluded pairs Medium = 1, Serum = 0)].
each well and plates were incubated at 37◦C with 5% CO2 for
2 h. Cell migration into the lower wells was counted using a
haemocytometer. The percentages of monocytes that migrated
with and without CCL2 and the percentage increase in monocyte
migration with CCL2 were calculated.
Monocyte Cytokine Secretion Assays
CD14+ monocytes were re-suspended in RPMI and 10% FCS at
a concentration of 1 × 106 cells per ml. 1ml cell suspension was
added per well into a 24 well-culture plate with and without the
potent monocyte stimulant bacterial lipopolysaccharide (LPS)
from Escherichia Coli O111:B4 (1 ng/ml; Sigma). Cells were
cultured for 24 h at 37◦C and 5% CO2. Post-culture supernatants
were separated by centrifugation at 350 g for 5min and stored at
−80◦C.
Cytokines were measured using a Mesoscale Discovery
(MSD) platform V-Plex Pro-inflammatory panel 1
electrochemiluminescence assay (IFN-γ, IL-1β, IL-2, IL-4,
IL-6, IL-8, IL-10, IL-12p70, IL-13, and TNF-α). The assays were
run according to the manufacturer’s instructions. Supernatant
samples were diluted 1:10 in the appropriate buffer and assayed
in duplicate.
Statistical Analysis
Between-group comparisons (PD vs. matched controls) were
performed using paired T-tests (IBM SPSS statistics version 25).
Experimental outliers with values >3 standard deviations (SD)
above or below the mean were excluded prior to analysis. Values
which were unpaired for any reason (e.g., outlier exclusion or cell
unavailability for assay completion) were automatically excluded
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TABLE 1 | Demographics of overall cohort.
Variable Patients Paired controls p
Number (n) 41 41
Age (years) 68.4 ± 6.3 68.1 ± 5.6 0.784
Gender (% male) 68.3 68.3 0.594
Disease duration (years) 4.2 ± 1.1
MDS-UPDRS motor score 35.2 ± 12.3
Equivalent Levodopa dose 591.5 ± 292.9
ACE-R score 92.9 ± 8.2
Values indicate Mean ± SD (Standard deviation); UPDRS, Unified Parkinson’s Disease
Rating Scale; ACE-R, Addenbrooke’s Cognitive Examination (Revised).
during the statistical analysis of paired T-tests. As analyses were
always performed as a comparison between paired PD and
control pairs, the exclusion of unpaired values did not influence
sample matching.
RESULTS
Participant Demographics
41 PD patients and 41 age and gender matched controls were
recruited in total. Demographic and clinical characteristics of the
cohort are shown in Table 1. Subsets of samples were used for
different functional assays depending on cell availability.
Monocyte Bead Phagocytosis
The latex bead phagocytosis assay was performed using both
standard medium (RPMI and 10% FCS) and freshly extracted
autologous serum. While autologous serum was used to partially
simulate the in-vivo intravascular environment, the standard
medium represented assessment of cell-intrinsic phagocytic
ability under standard culture conditions. A significantly higher
percentage of monocytes phagocytosed latex beads in the
presence of serum compared to standard medium (Figure 1), as
would be expected due to the increased presence of opsonizing
factors, such as antibodies and complement in autologous serum
(23–25).
Paired analysis indicated no differences in measures of bead
phagocytosis in standard medium between patients and controls
(Figure 1). However, with autologous serum, the bead positive
monocyte MFI ratio in patient monocytes was significantly
higher than in controls (p = 0.0286; Figure 1), indicating
increased uptake in PD bead positive monocytes compared to
controls. Patients also tended to have a higher overall serum bead
positive monocyte percentage, but this did not reach statistical
significance (Figure 1). There were no statistically significant
correlations between the uptake measures and clinical data,
including the UPDRS motor score, in this cohort.
The influence of serum factors on uptake was subsequently
examined in separate smaller ad hoc groups of patients and
controls. These groups included patients of later disease stage
compared to the original study, who otherwise fulfilled similar
criteria. The effect of swapping PD and control serum with their
paired monocytes was examined in 6 age and gender matched
PD and control pairs [age- (mean ± standard deviation (SD))
PD 72.67 ± 2.34, controls 68.00 ± 6.89 (p = 0.148); gender
83.3% male (PD and controls); PD disease duration (mean ±
SD) 7.35 ± 2.94]. The autologous serum bead positive monocyte
percentage was significantly higher in PD patients compared to
controls in this cohort (p = 0.0002; Supplementary Figure 2),
but this difference was no longer apparent when phagocytosis
was measured in the swapped, non-autologous serum condition
(p = 0.6541). Thus, the origin of the serum appeared to account
for the PD-control difference in monocyte phagocytosis (bead
positive monocyte percentage) seen with autologous serum
(Supplementary Figure 2).
Serum complement inactivation by heat treatment was
examined in PD (n = 6) and controls (n = 5) [age (mean
± SD) PD 72.0 ± 2.44, controls 66.25 ± 8.18 (p = 0.135);
gender PD 83.3% male, controls 80% male; disease duration
PD 7.50 ± 2.69]. Serum heat inactivation resulted in significant
decreases in autologous serum-based monocyte bead uptake in
both PD and controls [bead positive monocyte percentage (PD
p = 0.0001; controls p = 0.006); bead positive monocyte MFI
ratio (PD p = 0.0034; controls p = 0.0163)], indicating that
it had a significant effect on the overall level of phagocytosis
(Supplementary Figure 3). Bead positive monocyte uptake was
significantly higher in PD patients compared to paired controls
(p= 0.0087) in this cohort, but this significant difference was lost
post-heat inactivation (p= 0.0558; Supplementary Figure 3).
Monocyte Migration
There were no significant differences in monocyte migration
between this PD cohort and controls overall with or without the
presence of CCL2 (Figure 2A). Monocyte trans-well migration
levels were low in the baseline condition, but increased
significantly, as expected, in response to CCL2. However, there
was no difference in the magnitude of this response between PD
and controls (Figure 2B).
There were no significant differences between patients and
controls in the surface expression of the migration-associated
surface markers CCR2 and CX3CR1 (Supplementary Figure 4).
Migration measures also did not demonstrate any statistically
significant relationships with clinical data, including the UPDRS
motor score.
Monocyte Cytokine Secretion
Cytokine secretion in the unstimulated condition was low for
most cytokines and only IL-1β, IL-6, IL-8, IL-10, and TNF-
α had measurable results in >75% of participants. There were
no significant differences between paired patients and controls
(Table 2).
With LPS stimulation for 24 h, measurable concentrations
of all 10 cytokines were present in the supernatant in >75%
of participants. However, there were no statistically significant
differences between paired patients and controls overall in this
cohort (Table 2). There were also no statistically significant
relationships between cytokine secretion in either condition and
clinical measures.
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FIGURE 2 | (A) Graph showing percentage monocytes migrated in all PD patients and controls, with and without the presence of CCL2 as a chemoattractant. PD =
22, Controls = 22. (B) Graphs showing percentage increase in monocyte migration with CCL2 in all PD and controls.
TABLE 2 | Summary of unstimulated and LPS stimulated monocyte supernatant cytokine results.
Cytokine Cytokine concentration (pg/ml) ± SD
Unstimulated LPS Stimulated
Patients
(n = 20)
Paired controls
(n = 22)
p Patients
(n = 21)
Paired controls
(n = 23)
p
IFN-γ X X 46.09 ± 33.06 41.08 ± 35.00 0.764
IL-1β 42.74 ± 72.76 115.18 ± 232.63 0.176 771.38 ± 469.57 819.50 ± 500.82 0.222
IL-2 X X 17.28 ± 21.16 14.37 ± 15.05 0.604
IL-4 X X 4.87 ± 3.18 12.08 ± 16.68 0.082
IL-6 691.64 ± 2,027.38 1,060.22 ± 2,606.12 0.329 9,566.62 ± 4,558.47 10,024.70 ± 5,594.38 0.825
IL-8 28,776.83 ± 37,982.80 27,404.75 ± 39,478.76 0.591 126,025.80 ± 129,595.00 146,257.96 ± 166,969.57 0.794
IL-10 42.52 ± 104.54 63.59 ± 127.92 0.379 336.90 ± 235.92 327.90 ± 175.87 0.836
IL-12p70 X X 22.78 ± 13.19 19.01 ± 11.05 0.605
IL-13 X X 62.14 ± 51.80 50.93 ± 37.86 0.286
TNF-α 55.22 ± 123.60 215.93 ± 457.47 0.160 971.69 ± 612.36 962.76 ± 393.42 0.754
All results represent mean cytokine concentration (pg/ml) ± standard deviation (SD). p-values indicate significance on paired t-tests between matched PD and control pairs. X indicates
concentration above detection threshold in <75% of participants.
DISCUSSION
The findings demonstrate significantly increased monocyte
phagocytic capacity in an autologous serum environment
in PD, but no significant differences in standard medium-
based monocyte phagocytosis, monocyte migration or cytokine
secretion, compared to age and gender matched parallel
processed controls, in this cohort.
The use of the participant’s own serum as an environment
for the uptake assays attempted to more faithfully replicate
the intravascular in-vivo environment. The presence of serum
increased bead phagocytosis overall, compared to standard
medium in both PD and controls, consistent with the presence
of opsonising factors, such as antibodies and complement in the
serum (25, 26). Complement inactivation through heat treatment
had a profound negative effect on bead uptake in both PD and
controls, indicating an important contribution of complement to
serum-based monocyte phagocytosis (Supplementary Figure 2).
Interestingly, derivatives of complement factors, such as C3,
have been found to be higher in PD serum (27) compared to
controls and may contribute to the differences seen. We did
not specifically investigate the effect of serum antibodies in
this study, but they may also play an important role. Further
studies including antibody depletion and Fc receptor blocking
and measurement of serum complement and antibody levels will
be required to fully determine the factors responsible for the
serum assay differences observed.
Our data suggests that serum components in disease are an
important factor in determining the differential phagocytosis
observed between PD and controls. When the environmental
conditions are equal (standard medium) there is no significant
difference between PD and control monocyte phagocytosis,
whereas an autologous serum environment brings out a
difference. This indicates a strong influence from cell extrinsic
factors rather than cell-intrinsic factors in bringing about the
PD-control difference in phagocytosis observed in this study.
The data also suggests that swapping patient and control serum
with their paired monocytes removes this PD-control difference,
further supporting the hypothesis that external disease related
serum-based factors critically influence monocyte phagocytic
behavior.
In contrast to our study, previous studies investigating
monocyte phagocytosis in PD using standardmedium conditions
have found a relative impairment in PD compared to controls
in smaller numbers of participants (2, 3). The standard
medium bead phagocytosis assays in the current study, which
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would be most similar to those previous studies (3) did
not show a similar significant impairment. However, the
assays used in the previous studies utilized different types of
medium, different types and sizes of uptake particles (different
concentrations of 1µm beads, fluorescent red blood cells or
zymosan particles) and longer assay periods (up to 4 h) and
were also performed on relatively later stage PD patients (2, 3),
which may have contributed to the differences in outcome.
Shorter incubation periods used in the current study may
have also resulted in persistence of elements of influence
from the in-vivo environment, which may have affected the
results.
Previous studies have also shown the presence of differences
in monocyte surface markers and other cell-intrinsic factors in
PD vs. controls (3, 28). It is possible that intrinsic monocyte
differences may enhance or enable the effects of serum and
the overall phagocytosis level is likely to be influenced by a
combination and/or interaction of intrinsic and extrinsic factors.
Further studies investigating these factors in larger numbers of
PD and control pairs will be important to confirm and extend
these findings.
This was also the first study to assess monocyte migration
behavior in PD, and we found no significant overall differences in
standard medium based migration when compared to controls in
this cohort. One previous study has found increased expression
of the chemokine receptor CCR2 in PD monocytes compared
to controls (28), but our data did not replicate this finding.
Alpha-synuclein monomers and oligomers have been shown to
have monocyte and neutrophil chemoattractant properties (18),
but this was not assessed in the current study. Considering
the phagocytosis differences seen with autologous serum, it
would be interesting to also assess monocyte migration in
autologous serum, to investigate any differences which may be
revealed in this more in-vivo relevant environment. However,
these assays would need to be controlled for serum CCL2 and
other chemokine levels, which may be potential confounding
factors.
The current study showed no significant differences in
standard medium based monocyte cytokine secretion between
PD and controls. Previous studies using smaller sample sizes
have reported inconsistent results, with increased (3) or partially
decreased/unchanged (4) cytokine secretion by PD monocytes
with LPS stimulation compared to controls. The largest of
these (21 PD, 8 controls), reported no significant differences in
monocyte IL-1β, IL-6, IL-8, and IL-10 production, in keeping
with our study, but found a decrease in TNF-α secretion by PD
monocytes (4). Elevated cytokine production by PBMCs has also
been reported in PD compared to controls (29), suggesting that
other immune cell types may also be involved in the mediation of
an increased inflammatory response in PD patients.
As with migration, monocyte cytokine secretion could also be
assessed in autologous serum, but measurement of supernatant
cytokine levels would require controlling for serum intrinsic
cytokine levels. However, measurement of monocyte intracellular
cytokine levels using intracellular staining and flow cytometry
and cytokine gene expression may be alternative methods of
assessing cytokine secretion in the serum environment.
The functional assays were performed on positively selected
CD14+ monocytes and the overall functional status of total
monocytes will be influenced by the relative proportions of
the different monocyte subsets in PD and controls, with the
predominant classical monocytes (∼60–80% of total monocytes),
which have been found to be higher in PD, likely to have the
most influence on functions, such as phagocytosis (3). However,
this would not explain the presence of significant differences in
phagocytosis in autologous serum, but not in standard medium.
CD14+ selection may also lead to the relative loss of CD14
low non-classical monocytes, which may subsequently influence
the magnitude of any potential differences in non-classical
predominant cytokine secretion. Nevertheless, a previous study
demonstrating significant differences in monocyte secretion also
used CD14+ selection, suggesting that this may not be a major
factor (3). In general, the goal of the study was to obtain a
global overview of the status of total monocyte function in PD
compared to controls, while accepting that a variety of factors will
likely be contributing toward the overall picture.
It is possible that the use of CD14 positive magnetic bead
selection may have affected monocyte behavior (30). However,
both patient and control samples underwent the same process
of monocyte extraction and previous studies have also used this
method of monocyte isolation with differing results (3), hence it
is unlikely to be a major factor influencing differences between
PD and controls.
Most of the PD patients involved in this study were on
levodopa or dopamine agonist medications, and dopamine has
been reported to have effects on immune cells, including
augmentation of T follicular helper cell-B lymphocyte
interactions in germinal centers (31) and of monocyte functions,
such as migration (32). However, we found no significant
differences in monocyte migration behavior in PD when
compared to controls and this coupled to the finding of no
significant correlations between monocyte uptake measures or
other functions and levodopa equivalent dose in this study,
suggests that it is unlikely that these drugs could explain
the differences in behavior that we report. Dietary, circadian
and other medication factors may also potentially influence
monocyte function and serum. In this study all patients and
controls had samples taken within the same time period in the
morning and would have been expected to have had breakfast
and their regular medication prior to their visit. Further work
will require additional assessment of these assays in dopamine
medication naïve earlier stage PD patients and paired controls,
prior to food and medication intake in the morning.
It is possible that clinical subgroups of patients, with differing
levels of risk factors for cognitive and motor progression (33, 34)
may have differential differences compared to paired controls
and that potential differences are masked with the use of overall
combined analysis. This study did not have sufficient numbers
for each assay, to enable subgroup analysis. Future studies will
need to repeat these assays in larger numbers of different clinical
subgroups of patients to determine any underlying differential
changes seen only within specific clinical subgroups. The uptake
assays investigating serum factors provide some indication that
serum-based uptake is higher in PD even at later stages of disease.
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Thus, it will be important to assess monocyte function in larger
cohorts at different stages of PD, as well as longitudinally, in
order to identify any changes correlated with disease severity and
duration, which may be useful as potential biomarkers.
In conclusion, we have investigated a range of monocyte
functions in early-moderate PD compared to age and gender
matched controls and demonstrated an increased capacity for
bead phagocytosis in PD which appears to be mostly driven by
cell-extrinsic factors in PD serum. This adds to existing evidence
implicating changes in innate immune function in PD, but
further work will be required to investigate what serum factors
are important, as well as the physiological and clinical relevance
of these findings, particularly in relation to the disease process
and the alpha-synuclein pathology in PD.
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